General contact

E-mail Novartis Pharmaceuticals

1-888-NOW-NOVA (1-888-669-6682)
Monday - Friday, 8:30am - 5:00pm EST
In case of Medical Emergency, please contact your Physician immediately.

Customer Interaction Center
Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover, NJ 07936-1080
Please allow for mail processing and postal service turnaround time



US Pharma Media Relations

For reporters only. Consumers will be directed to

Anna Frable, Vice President
Novartis Pharmaceutical Corporation Communications

icon-phone.gif+1 862 778 5388 (for reporters only)
icon-fax.gif+1 732 673 5262


More Information


Novartis Patient Assistance

This program is for U.S. Residents only.

Monday - Friday, 8:30am - 5:00pm EST

Novartis Patient Assistance Program
PO Box 66556
St. Louis, MO 63166-6556

More Information

Patient Assistance for Medicare

Patient Assistance for Medicare Beneficiaries

Novartis encourages patients to review and enroll into Part D prescription drug plans because of the benefits that these plans offer patients for all or many of their prescription drugs. The Novartis Patient Assistance Foundation, Inc. (PAF) does not require Part D Plan enrollment but we feel that patients must consider the potential healthcare and financial benefits that these plans offer to them before determining not to enroll. To help assist PAP patients in understanding the Medicare Part D benefit and what Part D plan enrollment may offer to them, Novartis has set up a toll-free hotline to provide information and assistance. Novartis PAF patients can call 800-942-3424 for general information about the Part D benefit and can receive help in determining what plans are available to best meet their needs.

Medicare beneficiaries who enroll in a Part D plan may be considered for the Novartis PAF based upon the following criteria:

  • Patients on Novartis transplant or oncology products who enroll in a Part D plan can continue to receive help through the Novartis PAF as long as they continue to meet eligibility criteria for the PAF, do not qualify for the LIS, and show financial hardship in affording their medications despite the Part D benefit coverage;
  • Other cases will be evaluated individually, based on the particular Novartis product, specific circumstances and financial hardship experienced.